Barclays Initiates Coverage on Elanco Animal Health (NYSE:ELAN)

Equities researchers at Barclays started coverage on shares of Elanco Animal Health (NYSE:ELAN) in a note issued to investors on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $30.00 price target on the stock. Barclays‘s price objective would suggest a potential upside of 40.96% from the company’s current price.

ELAN has been the topic of a number of other research reports. UBS Group increased their price target on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. KeyCorp started coverage on shares of Elanco Animal Health in a report on Friday, November 21st. They set an “overweight” rating and a $27.00 target price for the company. Finally, Stifel Nicolaus increased their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.78.

Elanco Animal Health Stock Up 4.2%

Shares of ELAN stock opened at $21.28 on Tuesday. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $23.70. The stock has a market cap of $10.57 billion, a price-to-earnings ratio of 354.78, a PEG ratio of 2.77 and a beta of 1.86. The firm’s 50-day moving average is $21.70 and its 200-day moving average is $17.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business’s revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen LLC acquired a new stake in shares of Elanco Animal Health in the first quarter valued at approximately $115,212,000. UBS Group AG increased its stake in Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the period. Dimensional Fund Advisors LP raised its holdings in Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after acquiring an additional 2,563,740 shares in the last quarter. Jennison Associates LLC raised its holdings in Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after acquiring an additional 2,468,122 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.